Unjha Formulations Limited (BOM:531762)
India
· Delayed Price · Currency is INR 20.85
-0.10 (-0.48%)
At close: Apr 28, 2026
Unjha Formulations Revenue
Unjha Formulations had revenue of 44.39M INR in the quarter ending December 31, 2025, with 17.63% growth. This brings the company's revenue in the last twelve months to 148.12M, down -7.22% year-over-year. In the fiscal year ending March 31, 2025, Unjha Formulations had annual revenue of 139.30M, down -24.69%.
Revenue (ttm)
148.12M
Revenue Growth
-7.22%
P/S Ratio
0.63
Revenue / Employee
10.58M
Employees
14
Market Cap
93.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 139.30M | -45.67M | -24.69% |
| Mar 31, 2024 | 184.96M | 53.42M | 40.61% |
| Mar 31, 2023 | 131.54M | -10.24M | -7.22% |
| Mar 31, 2022 | 141.77M | 42.16M | 42.32% |
| Mar 31, 2021 | 99.62M | -8.50M | -7.86% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Decipher Labs | 148.66M |
| Vivanza Biosciences | 1.10B |
| Colinz Laboratories | 58.40M |
| Beryl Drugs | 176.65M |
| Ganga Pharmaceuticals | 26.93M |
| Ortin Global | 1.12M |
| Brawn Biotech | 172.71M |
| Desh Rakshak Aushdhalaya | 57.72M |